PEAK6 Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

PEAK6 Investments’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-8,907	Closed	-$1.14M	–	5366
2020 Q3	$1.02M	Buy	8,907 +4,904	+123%	+$529K	﹤0.01%	2256
2020 Q2	$449K	Sell	4,003 -72,498	-95%	-$7.7M	﹤0.01%	2773
2020 Q1	$6.87M	Buy	76,501 +68,283	+831%	+$6.7M	0.04%	417
2019 Q4	$889K	Sell	8,218 -39,469	-83%	-$4.22M	﹤0.01%	1599
2019 Q3	$4.67M	Buy	47,687 +35,504	+291%	+$4M	0.03%	712
2019 Q2	$1.6M	Buy	12,183 +5,799	+91%	+$747K	0.01%	1460
2019 Q1	$863K	Sell	6,384 -9,252	-59%	-$1.15M	0.01%	1961
2018 Q4	$1.52M	Sell	15,636 -5,015	-24%	-$593K	0.01%	1433
2018 Q3	$2.87M	Buy	+20,651	New	+$2.59M	0.01%	1170

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PEAK6 Investments's ALXN Position: Q4 2020 in Review

PEAK6 Investments sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 8,907 shares — an estimated $1.14M sold.

PEAK6 Investments first reported a position in ALXN in Q3 2018 and held it in 9 quarters. The position peaked at $6.87M in Q1 2020. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

PEAK6 Investments reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
PEAK6 Investments sold 8,907 Alexion Pharmaceuticals shares in Q4 2020, an estimated $1.14M.
PEAK6 Investments first reported a position in Alexion Pharmaceuticals in Q3 2018 and held it in 9 quarters.
PEAK6 Investments's Alexion Pharmaceuticals position peaked at $6.87M in Q1 2020.
827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on PEAK6 Investments's 13F filing for Q4 2020, filed 12 Feb 2021.